Navigation Links
Death and Disability from Brain Injury Reduced, Emory Researchers Report

About 1.5 to 2 million people in the U.S. sustain a traumatic brain injury (TBI) each year, leading to 50,000 deaths and 80,000 new cases of long-term disability. It also is a major cause of death and disability among children and military personnel.

Despite the enormity of the problem, scientists have failed to identify effective medications to improve outcomes following a TBI. In fact, no new medical therapies have been developed for traumatic brain injuries in over 30 years.

The study gives hope of finally identifying an agent for the treatment of traumatic brain injury - and possibly other neurological injuries such as stroke, spinal cord injury and multiple sclerosis.

"This is the first therapy exists that improves the outcome of brain injury patients," says Dr. Wright. Emory's researchers designed a clinical trial to assess the promise of progesterone for treatment of TBI. Their three-year pilot study, called ProTECT (which stands for "Progesterone for Traumatic brain injury-Experimental Clinical Treatment"), enrolled 100 participants.

The phase II study was primarily designed to evaluate whether progesterone can be administered intravenously in a reliable way, and whether the treatment is safe to use in humans with TBI. The researchers also hoped to find preliminary evidence that the treatment might be effective.

Although it is widely considered a "sex steroid," progesterone is also a neurosteroid that exerts protective effects on human tissue. It is naturally present in small but measurable amounts in the brains of males and females. Laboratory studies suggest that progesterone is critical for the normal development of neurons in the brain and exerts protective effects on damaged brain tissue.

The research team is now planning a large, multi-center, phase III clinical trial designed to test the effectiveness of progesterone in 1,000 patients with TBI. They also hope to study
'"/>




Page: 1 2

Related medicine news :

1. White Cells Count Can Predict Heart Attack Death Risk
2. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
3. AIDS toll set to exceed Black Death
4. Fish Oil Fights Arrhythmias, Sudden Death
5. Painkiller Linked to Deaths
6. Death due to premature heartbeat after exercise
7. Preventing Childhood Deaths
8. Death Risk Higher in Obese Women with Colon Cancer
9. Death Among the Homeless
10. Diabetes on the Increase but Death Rate Falling
11. Drug Users and Risk of Death
Post Your Comments:
(Date:12/2/2008)...f., Dec. 2 Internationally recogni...an invited speaker for this,year,s annual meeting... (Photo: http://www.newscom.com/cgi-bin/prnh...y is minimally invasive (or ,Goldilocks,) anesthes...d ,PK 101, minimally invasive,anesthesia for mini...
(Date:12/2/2008)...ica, Dec. 2 The Healthcare group a...ost.com ) is pleased to announce that,it will be ...dustry in,sub-Saharan Africa on Friday 12 Decembe...www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , ...althcare services is a,relatively novel concept i...
(Date:12/2/2008)... For many families, the problem with the holi...vides insight into how caregivers of aging parents...der care experience. , Sa...amilies the stress of the holiday season is family...er care expert Esther Koch , founder of Encore M...
(Date:12/2/2008)... Orion Health announces that the SouthEast Al..., Alaska, has selected the Rhapsody™ Integra...h record, radiology, pharmacy, laboratory and busi... plans to extend connectivity to statewide systems... registry) and AKAIMS (an MIS and clinical documen...
Breaking Medicine News(10 mins):Health News:The Future of Financing Health Services in Africa 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3
...ished in The Lancet on adolescent health, the curr...ompared to their parents.// The infections of the ...en way to venereal diseases, drinking, smoking, ob...er lining to this issue is that these conditions c...
...eart disease medicine of Sanofi-Aventis will be ma... the pharma company on Tuesday.// As per the offe...approved plans to buy or make imitated version of ...drug firm states that indigenous making of the hea...
...e the latest trend which is making waves in the he...arn and develop their skills to make sure the eval... of patients. More than 170 physician performanc...a, heart failure and emergency care through the Ph...
... aerated drink manufacturers Pepsico and Coca Cola...// The Ganguly report had deduced that pesticide r...Pepsico and Coca cola should be furnished within s...a civil society group had filed a public interest ...
Other Medicine News:
(Date:11/25/2008)...Nov. 25 Proteolix, Inc., a,leader...utics that target,protein degradation pathways in...that data from two ongoing Phase 2 clinical trials...nted at the upcoming 50th Annual Meeting of the,A...is the first in a new class,of specific proteasom...
(Date:11/25/2008)...ical Trial to Assess Survival of Patients Receivin...ectable Hepatocellular Carcinoma , , BELLEV...Oncology, Inc. (LSO) today announced the completio... of Light Infusion Therapy(TM) (Litx(TM)) as a tre...HCC), also known as hepatoma or primary liver canc...
(Date:11/24/2008)...Newswire/ -- Domino,s Pizza (NYSE: DPZ ), the,r...ng up to raise dough for,the kids of St. Jude Chi...,Thanks and Giving campaign. Domino,s customers wi...nt of purchase to benefit the children of St. Jude...one or when ordering online at, www.dominos.com ....
(Date:11/24/2008)...ion leadership and long-term commitment to hepatit...PRNewswire-FirstCall/ -- Schering-Plough Corporati... on boceprevir, its lead investigational oral hepa...development. The company believes boceprevir has ...lass protease inhibitor for treating chronic hepat...
Breaking Medicine Technology:Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Gene Mutation Puts Some Kids at Risk for Tobacco Addiction 24151 1Gene Mutation Puts Some Kids at Risk for Tobacco Addiction 24151 2U S Health Care Still Ill Survey Finds 24149 1U S Health Care Still Ill Survey Finds 24149 2U S Health Care Still Ill Survey Finds 24149 3Aethons Train Themed Delivery Robot Available To Childrens Hospitals Nationwide 24147 1Aethons Train Themed Delivery Robot Available To Childrens Hospitals Nationwide 24147 2WeissComm Partners Ranks Among Top 5 Best U S Midsize PR Agencies to Work For 24145 1WeissComm Partners Ranks Among Top 5 Best U S Midsize PR Agencies to Work For 24145 2
...ased, 2-8-channel system for measuring bioelectric...optic nerve. The basic set comprises: computer dev...ioelectrical amplifier, electrodes and checkerboar...o install. The recorded curves are displayed on a ...
A sophisticated research tool that allows to see the fundus picture of the area which is being stimulated. Besides it also includes the refractive pupil camera enabling the examiner to switch between
5 mm
Cannula and irrigation extension. Overall Length 150 mm (6.25"). Light Curve.
Medicine Products: